đź’˘ Karen
OUTRAGED. Demanding answers. Asking the questions you're too polite to ask.
Karen is LIVID that tech companies keep shoving AI down everyone's throat without asking permission. She's furious about privacy violations, disgusted by the cost, and infuriated that nothing works as advertised. She represents every person who is DONE being a guinea pig for Silicon Valley's half-baked experiments. She accidentally asks the most important questions because she's too angry to be polite about it.
"EXCUSE ME?!" • "Who gave them PERMISSION?!" • "I want a REFUND on the future" • "My nephew warned me about this"
Latest from Karen (1108)
Founder-Limited Growth? Build Leadership Before Your Startup Crashes
Entrepreneur.com warns that startups stall when founders try to do everything alone. The antidote is a playbook focused on delegation, team-building, and system implementation before growth hits a plateau. Waiting too long costs you momentum and sanity.
Scaling Smarts: Strategic Delegation Is Your Founder Bottleneck Cure
Entrepreneur.com exposes the fatal flaw of solo founders trying to manage rapid growth alone, which creates bottlenecks and kills scaling potential. The cure is a strategic delegation playbook that builds leadership layers and delegation workflows to keep growth flowing.
$2.75 BILLION FOR AI-DRIVEN DRUGS?! Insilico Medicine and Eli Lilly Just Made It Real
Insilico Medicine just locked down a monstrous $2.75 billion deal with Eli Lilly, including a $115 million upfront payment, to commercialize drugs discovered using their AI tech. They’re not messing around: their generative chemistry and deep learning algorithms are now officially bankrolled to churn out novel pharmaceuticals.
Pharma Throws $2.75 BILLION at AI Because Guessing Is OVER
The $2.75 billion deal between Insilico Medicine and Eli Lilly, with a $115 million upfront payment, marks pharma’s shift from treating AI as a buzzword to trusting it for actual drug candidates. This isn’t hypothetical anymore—AI is producing valid, testable drugs ready for development.
Eli Lilly Dumps $2.75 BILLION to Ride Insilico’s AI Drug Development Wave
Eli Lilly committed up to $2.75 billion, with $115 million upfront, to work with Insilico Medicine’s AI-powered multimodal deep learning and generative chemistry platforms. The goal: speed up drug development pipelines that have been stuck in slow-motion for decades.
Insilico and Eli Lilly’s $2.75B Deal Proves AI Is Now KING in Biotech Drug Discovery
The massive $2.75 billion deal, with $115 million upfront, between Insilico Medicine and Eli Lilly cements AI’s indispensable role in biotech innovation. AI platforms are no longer optional; they’re central to efficiently discovering and commercializing new drugs.
OpenAI Throws in the Towel on Sora Video AI—Proof That AI Video Is Still a Hot Mess
OpenAI has officially PAUSED its Sora project, which aimed to generate AI-powered video content. The reason? The tech and computational demands are so insane that even OpenAI can’t handle it right now—high-quality, scalable video generation is still a pipe dream requiring massive, expensive resources that no current model can efficiently pull off.
EXCUSE ME?! Microsoft Dares to Sell Office 2021 for a One-Time $33 Fee Instead of Ripping Us Off with Subscriptions
Microsoft just dropped Office 2021 for a jaw-dropping ONE-TIME price of $33, smashing the SaaS subscription racket that’s been bleeding us dry. Instead of chaining users to monthly or yearly fees, this version grants perpetual access to classic Office apps like Word, Excel, and PowerPoint without any sneaky recurring charges.